Navigation Links
NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
Date:7/11/2008

for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the timing of the completion of the Phase 1 clinical trial for NGX-1998; the potential to treat additional indications and skin locations with NGX-1998 than are currently targeted by NGX-4010; and the expected benefits of NeurogesX' potential products, including its liquid formulation product candidate NGX-1998 and its lead product candidate NGX-4010. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, NeurogesX' product candidate may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010 or NGX-1998, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NGX-4010 or NGX-1998 and the advantages of NGX-4010 or NGX-1998 over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

NeurogesX The Ruth Group

Stephen Ghiglieri Investors / Media

(650) 358-3310 Stephanie Carrington / Jason Rando

sghiglieri@neurogesx.com (646) 536-7017 / 7025

scarrington@theruthgroup.com<
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
2. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
3. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
4. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
5. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
6. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
9. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
10. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
11. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 26, 2014  Aridis Pharmaceuticals, Inc., a biopharmaceutical ... for infectious diseases, announced today the addition of ... key opinion leader in the areas of pneumonia ... Founder and Chief Executive Officer, ... Opal,s extensive experience investigating bacterial toxins and key ...
(Date:11/26/2014)... and LONDON , Nov. ... market intelligence, MarketResearch.com is pleased to announce the distribution ... Consultancy focusing on the active pharmaceutical ingredient (API) market. ... http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 . In IQ4I,s newest ... Forecast to 2020 , IQ4I analysts ...
(Date:11/26/2014)... Nov. 25, 2014  At the American Dental Association,s ... this October, KaVo Kerr Group was honored to be ... attendees the opportunity to see and test the Best ... leaders deliver lectures on the latest developments in dental ... the new DEXIS CariVu Caries Detection Device and Kerr ...
Breaking Medicine Technology:Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 3
... 23, 2011 /PRNewswire-Asia/ -- Golden Meditech Holdings Limited ... integrated healthcare enterprise, today announced that the Group has accumulated ... Corporation ("CCBC," - CO.US) from the open market between December ... Group now owns 39.5% of the issued share capital of ...
... Four hospitals serving Virginia patients reduced healthcare-acquired infection rates ... in savings of $1.2 million in additional costs to ... plan to existing federal hand washing protocols, these hospitals ... and reduced patient length-of-stay and unnecessary readmissions. ...
Cached Medicine Technology:Golden Meditech to Increase Stake in NYSE-listed Affiliate -- China Cord Blood Corporation to 39.5% 2Virginia Hospitals Reduce Infections 41% 2Virginia Hospitals Reduce Infections 41% 3
(Date:11/28/2014)... November 28, 2014 Novatus, a ... its Release v5.1 which provides customers with greater ... options. , “As we continue to evolve ... provide more functionality and improved performance in response ... CEO for Novatus. “With the enhancements that we ...
(Date:11/28/2014)... 28, 2014 Dr. Andrew Campbell, one ... announced the expansion of Quintessa Aesthetic Center into a ... located at W307 N1497 Golf Road in Suite 200 ... Dr. Campbell, the new Delafield location will offer a ... patients, including: Botox, filler injectables , micro laser ...
(Date:11/28/2014)... Dr. Paul Vitenas, one of the most awarded cosmetic surgeons ... for those in the area that would like to learn more ... will take place on December 11, 2014, from 6:00 p.m. until ... Houston at 4208 Richmond Ave. , “We want to wish ... and celebrate the season with us on December 11, 2014 from ...
(Date:11/28/2014)... Evergreen, Colorado (PRWEB) November 28, 2014 Written ... Jackson , Brook Forest Voices releases the “The Happiest ... audiobook , a compelling account of how and why Project ... of Idaho by his mother Josie and the Reverend Richard ... millionaire by the age of 30, but realized that he ...
(Date:11/28/2014)... Alex Kramer HealthDay Reporter , ... in the kitchen, through cooking classes or at home, may ... a recent review. Cooking programs and classes for children ... to the new research. And, although the review didn,t look ... such programs might help children develop long-lasting healthy habits. ...
Breaking Medicine News(10 mins):Health News:Novatus Releases v5.1 with New Advanced Reporting Capabilities 2Health News:Dr. Andrew Campbell to Expand Quintessa Aesthetic Center into Delafield 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 3Health News:Thanksgiving Weekend Audiobook Treat! “The Happiest Man In the World: Life Lessons From a Cultural Economist” by Dr. James W. Jackson 2Health News:Want Kids to Eat Better? Get Them Cooking 2Health News:Want Kids to Eat Better? Get Them Cooking 3
... , , WEDNESDAY, April 22 (HealthDay News) -- Responding to ... Administration said Wednesday that it will now allow 17-year-olds ... a doctor,s prescription. , In 2006, the FDA ... also known as Plan B, to women 18 and ...
... 22 NuVasive, Inc. (Nasdaq: NUVA ), ... minimally disruptive surgical treatments for the spine, announced today ... New Jersey based company focused on clinical approval of ... disc replacement device. This strategic acquisition allows NuVasive the ...
... TMK ) reported today that for the quarter ... (after a charge of $.49 per share for impairment of ... quarter. Net operating income for the quarter was $1.49 ... per share for the year-ago quarter. Reconciliations between net income ...
... of drinking while pregnant, , , WEDNESDAY, April 22 (HealthDay ... and mental problems in babies born to women who ... known that drinking while pregnant can be harmful to ... to children with noticeable deficits, noted Chris Downing, a ...
... AMICAS, Inc. (Nasdaq: AMCS ), a ... solutions, today announced it will report the company,s financial ... after the market closes on Monday, May 11, 2009.(Logo: ... of its financial results, management will host a conference ...
... To Webcast Annual Shareholders MeetingLIONVILLE, Pa., April 22 ... announced today that it will release 2009 first quarter ... 30, 2009, and will follow with a conference call ... a.m. Eastern Time. To participate on the call, please ...
Cached Medicine News:Health News:FDA Approves 'Plan B' Pill for 17-Year-Olds 2Health News:NuVasive Announces Acquisition of Cervical Total Disc Replacement Device 2Health News:NuVasive Announces Acquisition of Cervical Total Disc Replacement Device 3Health News:NuVasive Announces Acquisition of Cervical Total Disc Replacement Device 4Health News:Torchmark Corporation Reports First Quarter 2009 Results 2Health News:Torchmark Corporation Reports First Quarter 2009 Results 3Health News:Torchmark Corporation Reports First Quarter 2009 Results 4Health News:Torchmark Corporation Reports First Quarter 2009 Results 5Health News:Torchmark Corporation Reports First Quarter 2009 Results 6Health News:Torchmark Corporation Reports First Quarter 2009 Results 7Health News:Torchmark Corporation Reports First Quarter 2009 Results 8Health News:Torchmark Corporation Reports First Quarter 2009 Results 9Health News:Torchmark Corporation Reports First Quarter 2009 Results 10Health News:Torchmark Corporation Reports First Quarter 2009 Results 11Health News:Torchmark Corporation Reports First Quarter 2009 Results 12Health News:AMICAS Schedules First Quarter 2009 Earnings Results Conference Call 2Health News:West to Host 2009 First Quarter Conference Call 2
... Resistant Tips offer a safe alternative to ... designed for applications such as PCR(a), pipetting ... ART Tips are excellent for tissue culture, ... ART Tips prevent aerosol contaminants and liquids ...
... wide orifice tip, the Finntip Wide is ... and macromolecules like genomic DNA. This tip ... fragmentation. It is excellent for use with ... the inside diameter of the orifice is ...
... designed to optimize the accuracy and precision ... products is widely recognized by customers throughout ... extended over the years and now covers ... tips including filter tips, certified pure tips, ...
... plastic-wrapped racks of 96 tips, Sterilized Diamond- ... autoclave. Sterilized Diamond Tips are irradiated by ... delivered with a certificate of sterilization, specifying ... are certified free of detectable Rnase, Dnase, ...
Medicine Products: